Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Registration Number
- NCT00082251
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT00080275
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
- Conditions
- DyslipidemiaCoronary Heart DiseaseAtherosclerosisStrokeDiabetes
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00079638
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
- Conditions
- Intermittent ClaudicationPeripheral Vascular Disease
- First Posted Date
- 2003-10-20
- Last Posted Date
- 2006-11-02
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 870
- Registration Number
- NCT00071266
- Locations
- 🇺🇸
Penn State College of Medicine, Hershey, Pennsylvania, United States
🇺🇸North County Internal Medicine, Vista, California, United States
🇺🇸Care Foundation, Inc, Wausau, Wisconsin, United States
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
- Conditions
- Intermittent ClaudicationPeripheral Vascular Disease
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 366
- Registration Number
- NCT00062556
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
- Conditions
- HIV InfectionsHypercholesterolemiaHypertriglyceridemiaDiabetes Mellitus
- First Posted Date
- 2002-09-25
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 30
- Registration Number
- NCT00046267
- Locations
- 🇺🇸
Washington Univ (St. Louis), St. Louis, Missouri, United States
🇺🇸Stanford Univ, Stanford, California, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
HDL-Atherosclerosis Treatment Study (HATS)
- Conditions
- Coronary DiseaseCardiovascular DiseasesHeart DiseasesMyocardial Ischemia
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- University of Washington
- Registration Number
- NCT00000553
Coronary Drug Project
- Conditions
- Cardiovascular DiseasesCoronary DiseaseMyocardial IschemiaHeart DiseasesMyocardial Infarction
Coronary Drug Project Mortality Surveillance
- Conditions
- Cardiovascular DiseasesCoronary DiseaseHeart DiseasesMyocardial IschemiaMyocardial Infarction
Cholesterol-Lowering Atherosclerosis Study (CLAS)
- Conditions
- Cerebral ArteriosclerosisArterial Occlusive DiseasesCardiovascular DiseasesCoronary DiseaseCarotid Artery DiseasesCoronary ArteriosclerosisCerebrovascular DisordersHeart DiseasesMyocardial IschemiaAtherosclerosis
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.